Literature DB >> 9454803

Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity.

K M Wasan1, M Ramaswamy, W Wong, P H Pritchard.   

Abstract

The purpose of this study was to determine if lipid transfer protein (LTP I) regulates the plasma lipoprotein distribution of cyclosporine (CSA). Experimental strategies that involved the supplementation and inhibition of LTP I were used to test these hypotheses. Incubation of CSA with human plasma supplemented with exogenous LTP I resulted in a significantly greater percentage of CSA recovered in the high-density lipoprotein (HDL)/lipoprotein deficient plasma (LPDP) fraction than in the low-density lipoprotein (LDL)/very low-density lipoprotein (VLDL) fraction compared to plasma which had no exogenous LTP I added. Incubation of radiolabeled cholesteryl ester (CE) or CSA-enriched HDL or LDL in T150 buffer supplemented with LTP I resulted in a significantly greater percentage of CE than CSA being transferred from HDL to LDL and LDL to HDL. However, the percent transfer from LDL to HDL was significantly lower for CE than CSA when these particles were incubated in LPDP that contained endogenous LTP I. The percent transfer of CE from HDL to LDL and LDL to HDL was significantly decreased in the presence of TP2, a monoclonal antibody directed against LTP I, compared to controls. The percent transfer of CSA from LDL to HDL was significantly decreased in the presence of TP2. However, the percent transfer of CSA from HDL to LDL in the presence of TP2 was not significantly different compared to controls. These findings suggest that the transfer of CSA between HDL and LDL is only partially facilitated through LTP I CE transfer activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454803

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

2.  Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics.

Authors:  Mohamad Firas Bassissi; Michel Alvinerie; Pascal Guy Pierre Martin; Bertrand Perret; Anne Lespine
Journal:  Pharm Res       Date:  2006-09-15       Impact factor: 4.200

3.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

4.  Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins.

Authors:  Kishor M Wasan; Olena Sivak
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

5.  Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.

Authors:  Olena Sivak; Benny Lau; Nilesh Patankar; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

6.  Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Authors:  Kishor M Wasan; Olena Sivak; Richard A Cote; Aaron I MacInnes; Kathy D Boulanger; Melvyn Lynn; William J Christ; Lynn D Hawkins; Daniel P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Cyclosporine binds to the neutral lipid and potentially other binding sites of lipid transfer protein I.

Authors:  Mona Kwong; Kishor M Wasan
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.